MFN changing the rules of the game for the Nordic countries

Eoin Ryan

Mon, April 27, 2026 astatine 10:36 AM CDT 4 min read

Innovative pharmaceutical commercialized associations crossed the Nordic portion person reacted with vigilance to a caller study by GlobalData that highlighted the imaginable effect connected merchandise motorboat and withdrawal trends successful Europe caused by the Most Favored Nation (MFN) argumentation successful the US.

Recent GlobalData Price Intelligence (POLI) investigation showed a 35% diminution successful pharmaceutical launches crossed Europe successful the 10 months aft the instauration of planetary notation pricing (IRP) successful the US. While different factors specified arsenic regulatory delays, pricing and reimbursement negotiations, proviso concatenation constraints, manufacturing constraints, oregon failed tract inspections, successful summation to MFN, volition beryllium astatine play, impacting the diminution successful launches, it has nevertheless drawn adjacent attraction from the Danish Association of the Pharmaceutical Industry (LIF) and Swedish Association of the Pharmaceutical Industry (LIF), respectively. A study by Sweden’s LIF spotlights POLI information to amusement that the archetypal effects of MFN connected diligent entree to caller medicines successful Europe tin already beryllium detected. Indeed, POLI suggests that Sweden has been disproportionately impacted by merchandise motorboat delays and merchandise withdrawals since the imposition of MFN. This is linked to ex-manufacturer prices successful the Nordic countries being beneath the European average. Based connected GlobalData Price Intelligence investigation of a illustration of 21 oncology products that received regulatory support aft 2020, and that are priced successful 20 oregon much European markets, the mean terms per spot portion (€/unit/mg) is 5% little successful the Nordic markets combined compared to the European average.

The prevailing interest that MFN could harm entree to medicines successful the Nordic portion is besides reflected successful an manufacture survey of pharmaceutical companies carried retired by Sweden’s LIF commercialized association, the results of which amusement a ample bulk of manufacture respondents expect large shifts successful motorboat strategies successful the portion implicit the coming years. The LIF manufacture questionnaire compares to a GlobalData State of the Biopharmaceutical Industry survey, published successful December 2025, successful which respondents were asked whether the US MFN argumentation volition oregon volition not interaction their company’s strategy. At the time, GlobalData survey respondents were divided 41% “yes” to 32% “no” with 27% undecided. The LIF survey suggests that “yes” is present progressively the default reply for astir pharmaceutical companies operating successful Sweden and the wider Nordic region.